Theratechnologies Announces Financial Results for the Second Quarter of 2018

Pharmaceutical Investing

Theratechnologies (TSX:TH) announced its financial results for the second quarter ended May 31, 2018. As quoted in the press release: “Although we are at a very early stage in the commercialization of Trogarzo™ in the U.S., we can appreciate the positive impact it is having on our bottom line. Given the positive response from patients, …

Theratechnologies (TSX:TH) announced its financial results for the second quarter ended May 31, 2018.

As quoted in the press release:

“Although we are at a very early stage in the commercialization of Trogarzo™ in the U.S., we can appreciate the positive impact it is having on our bottom line. Given the positive response from patients, physicians and payers, Trogarzo™ sales are gradually picking up steam and we should continue to observe the benefits of our new product to our results,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
Second quarter 2018 financial results
Consolidated revenue for the three- and six-month periods ended May 31, 2018 was $12,326,000 and $22,544,000 compared to $10,016,000 and $19,051,000 for the same periods ended May 31, 2017, an increase of 23.1% and 18.3% respectively. Revenue growth for the last quarter compared to the same quarter last year reflects the added contribution of Trogarzo™.

Click here to read the full press release.